Christian Ammitzbøll RheumTweeter
3 years 3 months ago
Overview of treatment strategies in #Lupus #EULAR2023 #Rheumtwitter https://t.co/zL1nEDajsb
Dr. John Cush RheumNow
3 years 3 months ago
RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow
3 years 3 months ago
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5
An artificial intelligence model to assess pre-RA hand MRIs has confirmed what human readers have known before: that bone marrow edema and tenosynovitis are objectively the best predictors of future RA development in patients with clinically suspect arthralgias or undifferentiated arthritis.
David Liew drdavidliew
3 years 3 months ago
75 different biosimilars in Europe, and nearly 20 years since the journey started. @EMA_News has led the world on biosimilars #EULAR2023 @RheumNow https://t.co/LFs3FR9dfW
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies. But, what about the JAKis and Tyk2 oral drugs in SLE?
Aurelie Najm AurelieRheumo
3 years 3 months ago
Would you rather have Erosive hands OA or RA?
130+ EHOA and 370+ RA, dis duration > 10 yrs for both cohorts
📍EHOA associated w/ > pain & functional impairment
📍RA associated w/ > comorbidities
@RheumNow #EULAR23 POS0103 https://t.co/KdDG7E6PZw
Aurelie Najm AurelieRheumo
3 years 3 months ago
A model predicts development of PsA in PSO cohort at 1 yr w/ AUC 72.3
Risk factors:
✔️younger age
✔️male
✔️family hx of PSO
✔️back stiffness
✔️nail pitting,
✔️stiffness
✔️PGA
✔️bioDMARDs
5yr prediction model AUC 75
Promising but to be confirmed
@RheumNow #EULAR23 POS0019 https://t.co/boCYOH2sDS
Dr. John Cush RheumNow
3 years 3 months ago
@RheumNow hard at work, shooting KOL videos, at #EULAR2023 https://t.co/C9n2218oeU
Aurelie Najm AurelieRheumo
3 years 3 months ago
ANSWER cohort
Retrospective study 6600+ bio/tsDMARDs ttmt courses, 20 yrs
✔️IL-6Ri is the lowest discontinued for lack of efficacy
✔️CTLA4-Ig is the lowest discontinued due to AEs
✔️Concomitant GC ⬆️30% drug discontinuation due to AEs
@Rheumnow #EULAR23 POS0051 https://t.co/8e6U5KHmX4
Aurelie Najm AurelieRheumo
3 years 3 months ago
The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8)
Use of TNFi & orthopedic implants associated w/ OAI risk
Mortality however similar in RA and non RA groups
@RheumNow #EULAR23 POS0033 https://t.co/H6JYkbNu0B
Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. Traditionally, a bimodal distribution by age has been reported with peaks at the ages of 15 to 25 and between 36 to 46.
David Liew drdavidliew
3 years 3 months ago
Always great to have @EMA_News to come and to talk to us at #EULAR2023
Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍
@RheumNow https://t.co/hSutraUsFD
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 3 months ago
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC
